Skip to main content
Premium Trial:

Request an Annual Quote

GeneTrove, Pharmacia Ink Antisense R&D Collaboration

NEW YORK, March 27 - Isis Pharmaceuticals on Wednesday said that its GeneTrove division will allow Pharmacia to use its antisense inhibitors to validate targets in genes that the biotech company selects.

Pharmacia will also license undisclosed IP from Isis' functional-genomics suite.

Terms of the deal call for Isis to design and deliver antisense inhibitors to Pharmacia. While financial terms of the deal were not disclosed, Isis will maintain the rights to develop antisense drugs to those genes, the company said.


Isis' functional-genomics IP suite comprises approximately 50 patents and applications, a main component of which is RNase H, a naturally occurring cellular enzyme that cleaves the RNA portion of an RNA/DNA duplex.

The Scan

Support for Moderna Booster

An FDA advisory committee supports authorizing a booster for Moderna's SARS-CoV-2 vaccine, CNN reports.

Testing at UK Lab Suspended

SARS-CoV-2 testing at a UK lab has been suspended following a number of false negative results.

J&J CSO to Step Down

The Wall Street Journal reports that Paul Stoffels will be stepping down as chief scientific officer at Johnson & Johnson by the end of the year.

Science Papers Present Proteo-Genomic Map of Human Health, Brain Tumor Target, Tool to Infer CNVs

In Science this week: gene-protein-disease map, epigenomic and transcriptomic approach highlights potential therapeutic target for gliomas, and more